Page 63 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

69. Wang SM, Colombara D, Shi JF, et al. Six-year regression and progression of cervical lesions
of different human papillomavirus viral loads in varied histological diagnoses. International
journal of gynecological cancer : official journal of the International Gynecological Cancer 2 Society. 2013;23(4):716-23.
70. Kim JW, Song SH, Jin CH, Lee JK, Lee NW, Lee KW. Factors affecting the clearance of high-risk human papillomavirus infection and the progression of cervical intraepithelial neoplasia. The Journal of international medical research. 2012;40(2):486-96.
71. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002;11(5):483-8.
72. Peng S, Trimble C, Wu L, et al. HLA-DQB1*02-restricted HPV16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV16-associated high-grade squamous intraepithelial lesions. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(8):2479-87.
73. Manawapat A, Stubenrauch F, Russ R, Munk C, Kjaer SK, Iftner T. Physical state and viral load as predictive biomarkersfor persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study. American journal of cancer research. 2012;2(2):192-203.
74. Li W, Wang W, Si M, et al. The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma. Journal of cancer research and clinical oncology. 2008;134(12):1355-61.
75. Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. BioMed research international. 2013;2013:519619.
** this review provides an overview of current knowledge on validated and candidate biomarkers, mostly diagnostic
76. Kruse AJ, Skaland I, Janssen EA, et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2004;23(2):100-9.
77. Quint KD, de Koning MN, Quint WG, Pirog EC. Progression of cervical low grade squamous intraepithelial lesions: in search of prognostic biomarkers. European journal of obstetrics, gynecology, and reproductive biology. 2013;170(2):501-6.
78. Baak JP, Kruse AJ, Garland SM, et al. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. The American journal of surgical pathology. 2005;29(8):1062-6.
79. Kruse AJ, Baak JP, Janssen EA, et al. Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki67 immuno-quantitative variables. The Journal of pathology. 2003;199(4):462-70.
A review of prognostic biomarkers
61